This clinical trial is focused on studying the safety of a treatment for a condition called geographic atrophy, which is a progressive eye disease that affects the retina and can lead to vision loss. The treatment being studied is called avacincaptad pegol, also known by its code name ARC1905. This medication is administered as a solution for injection directly into the eye, a method known as intravitreal use. The purpose of the study is to assess the long-term safety of this treatment in patients who have already participated in a previous study called ISEE2008 (GATHER2).

During the course of the study, participants will receive monthly injections of avacincaptad pegol for a period of up to 17 months. Some participants may receive a placebo instead. The study will monitor participants for any adverse effects, which are unwanted or harmful reactions to the treatment. Additionally, the study will evaluate the body’s immune response to the medication, known as immunogenicity, and how the drug is processed in the body, referred to as pharmacokinetics.

This study is an open-label extension, meaning that both the researchers and participants know which treatment is being administered. It is designed for patients who have completed the previous study and aims to provide further insights into the safety of avacincaptad pegol for treating geographic atrophy. The study is expected to conclude in April 2025.